Baidu
map

医学影像临床应用发展趋势 影像新技术给力SCI论文发表

2011-03-27 MedSci MedSci原创

医学影像临床应用发展趋势 影像新技术给力SCI论文发表--第一届国际医学影像临床应用与学术论着发表策略研讨会上海隆重召开 生物谷Bioon.com 上海讯 2011年3月26日,第一届国际医学影像临床应用与学术论著发表策略研讨会在上海复旦大学医学院明道楼隆重召开。来自业内专家、学者、医生及科研工作者二百人参加了此次盛会。本次研讨会由中国专业科研与临床学术服务领先提供商、国内科研与临床教育、培

医学影像临床应用发展趋势 影像新技术给力SCI论文发表
--第一届国际医学影像临床应用与学术论着发表策略研讨会上海隆重召开

生物谷Bioon.com 上海讯 2011年3月26日,第一届国际医学影像临床应用与学术论著发表策略研讨会在上海复旦大学医学院明道楼隆重召开。来自业内专家、学者、医生及科研工作者二百人参加了此次盛会。本次研讨会由中国专业科研与临床学术服务领先提供商、国内科研与临床教育、培训的拓展者MedSci主办。复旦大学生物医学研究院(IBS)为本次会议的支持单位。


(会议现场 生物谷Bioon.com 摄)

本次研讨会以临床研究设计、医学影像学和放射领域国际最新进展为起点,以促进临床科研成果国际化为目的,围绕医学影像学和放射领域最新进展、科研立题、论文写作和基金申请等核心环节,进行深刻有效地探讨。


(李明华教授精彩报告 生物谷Bioon.com 摄)

上海影像研究所所长李明华教授为此次大会开幕致辞,李明华教授称,写出好文章并分享最新的医学影像学临床应用,对于医学影像的发展起着重要的推动作用。李明华教授长期从事神经影像诊断和神经介入治疗的临床研究,擅长脑血管性病变、脊柱脊髓病变的影像学诊断和介入治疗。李明华教授就神经血管影像学新进展作专题报告,报告通过具体案例就微血管、血管壁、脑动脉瘤无创成像作了深入分析。


(Radiology主编Mark.Schweitzer精彩报告 生物谷Bioon.com 摄)

医学影像学已成为与外科、内科并列的第三大治疗手段,但是发表一篇高水平SCI论文并不简单,来自国际知名学术杂志Radiology主编 Mark.Schweitzer博士《在国际一流期刊上发表论文的写作策略》报告中从论文的不同部分的写法和注意事项,为广大科研人员的提供了新思路。

具体结合到影像学及相关杂志发表策略,Psychiatry Research: Neuroimaging杂志联合主编Thomas Dierks博士认为不要患"因子偏执症",不要把影像因子或引用作为唯一的考虑,最合适的就是最好的。MedSci首席科学家陈鹂博士认为在撰写SCI 文章中,应用影像和放射写真具体清晰说明病例、病理时,可以利用3D角度(技术、应用、病种)思考,并撰写出出色的SCI论文。她以弥散加权成像(DWI)为例,具体说明了怎样应用3D角度,具体撰写SCI论文,众多参会者表示受益匪浅。

来自同济大学附属第十人民医院程英升副院长,谈到医学影像临床科研整理与成果发表时,从题目、摘要、前沿、材料和方法、结果、讨论以及致谢和参考文献的几个方面结合个人心得体会做了精彩报告。程英升教授认为,SCI论文发表对科研工作者十分重要,并特别指出,近年来,致力于SCI学术论文发表支持的机构如雨后春笋,但是,经过这两年的比较,MedSci已经在学术性、专业度及品牌度成为了行业内值得信赖的科研与临床学术服务提供商。(生物谷Bioon.com)

# # #

关于MedSci

MedSci是中国专业科研与临床学术服务领先提供商,也是中国科研与临床教育、培训的拓展者。汇聚来自全球著名高校的300多名医药、生物专业博士团队的雄厚学术力量, MedSci致力于搭建中国与世界医学、生物科研互动的桥梁,为中国科研与临床学术研究提供专业的技术指导与学术支持。多年来,MedSci专注于医学生物领域,已服务70多个细分学科的两万多名客户,成功协助他们开展科学研究,并帮助其在第一时间将临床发现与科研成果展现给世界的同行们。目前,MedSci 主要提供SCI学术论文发表支持,基金申请咨询/标书修改,科研方案设计咨询,实验技术指导,资料统计挖掘,论文写作指导,科研教育培训,学术会议支持,产品学术推广等。 MedSci将凭借独特的学术背景和技术优势为客户提供专业的"一站式"科研学术服务。

关于复旦大学生物医学研究院(Institutes of Biomedical Sciences, IBS)

始建于2004年3月,是国家985二期工程建设的科技创新平台。研究院的宗旨是:"健康上海人,欢乐中国人"。研究院遵循"章鱼模式"发展,建设人才聚集高地、领衔大项目高地和做一流研究高地。研究院以"转化医学"为目标,积极推动复旦大学生命科学与医学的有机结合,建立基础科学与临床需求的紧密联系。 研究院的院训是"铭诚、卓毅、协作、拓新"。 生物医学研究院实行平台管理委员会领导下的首席科学家负责制,管理上遵循国际通用的PI管理模式。研究方向以国家中长期科技规划以及国家、上海市的经济建设和社会发展设计组织项目申请和团队建设为出发点,设立的主要研究方向包括:疾病系统生物学、出生缺陷与发育生物学、疾病发生的分子机制、创新药物和结构生物学等。研究院现拥有院士7名,全时引进PI 20人,分时引进PI 8人,双聘PI 43人,研究人员20余名,工程技术人员20余名。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1835544, encodeId=b44f183554465, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Nov 16 18:23:00 CST 2011, time=2011-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903627, encodeId=8b2c190362ecd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Mon May 02 00:23:00 CST 2011, time=2011-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897654, encodeId=7272189e65409, content=<a href='/topic/show?id=892d3e85304' target=_blank style='color:#2F92EE;'>#发展趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37853, encryptionId=892d3e85304, topicName=发展趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jun 28 13:23:00 CST 2011, time=2011-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404428, encodeId=9dda140442899, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466457, encodeId=2b58146645e9a, content=<a href='/topic/show?id=04469139114' target=_blank style='color:#2F92EE;'>#论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91391, encryptionId=04469139114, topicName=论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37e96815787, createdName=yeaweam, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561929, encodeId=db6615619294c, content=<a href='/topic/show?id=d7e5160350d' target=_blank style='color:#2F92EE;'>#SCI论文发表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16035, encryptionId=d7e5160350d, topicName=SCI论文发表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 29 14:23:00 CST 2011, time=2011-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095, encodeId=0473209562, content=谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=郭, createdTime=Sun Mar 27 23:27:00 CST 2011, time=2011-03-27, status=1, ipAttribution=)]
    2011-03-27

    谢谢,收获很多,MedSci为我们请来了真正的国际大牛。不知下次会议有没有类似的人物?

    0

相关资讯

临近毕业,快速发表SCI文章秘诀

我先抛砖引玉下。1。要选对课题。课题缺乏新意,是很难发的。我开始的课题无聊之极,我给它大大的给了一下。2。要不断调整实验的方向。这需要不断的阅读文献。3。要不断积累知识。可以跟踪国际上同行发表的最新成果。比如现在做神经再生的在增多,做凋亡已经不新鲜了,除非你做的很深入。比如王晓东教授在凋亡方面做得很深入。4。要早下手写。可以先写前言、方法等。5。好的英语句子一定要多积累,好的文章多读。高档杂志的文

国家自然科学基金评审意见[绝密]

MedSci: 根据这些评审意见,我们知道评委看问题的角度,以及结合这些意见,认真审查自己的标书,力所能及避免这些缺陷。从而使标书更有说服力,更容易中标。 标书能否中标一般取决于以下几个方面: (1)核心点是文章的创新性。一般建议选择近年来热点领域,在此基础上略作探索和深入,一方面评委对此领域较为熟悉,二是容易引起兴趣。当然,选择冷门也行,但是要说得容易理解。(2)标书story要完整,设计要

国家自然科学基金申请书写作全攻略

国家自然科学基金申请书写作全攻略 指导思想篇 1、 追求卓越,在知识上要绝对专业,坚决反对侥幸心理。 2、 相信NSFC申请是公平的,大家靠实力竞争,必须花大力气写标书;如果你认为NSFC只有关系,你就不用继续往下看了。 3、 NSFC是一个系统工程,需要花很多时间和精力,而不仅仅是几页标书,是智慧沉淀的结晶。 4、 不要把NSFC看的高不可及,你要相信自己的创意,哪怕你只是一

MedSci新增全国免费科研服务热线: 400-6408-988

为了方便广大客户与我们联系,我们不仅开通了多门电话,在线留言,在线客服,但是仍然有不少用户无法打进电话(电话可能处于占线之中)。因此,又特开设400全国免费电话,无论是手机,还是固话,均可以拨打:400-6408-988,如果是我们的办事处或分公司地方,电话会直接转接至我们的当地销售顾问,更方便地为您提供服务和咨询。 M

MedSci参加2010干细胞技术与应用讲座

    为期两天的2010干细胞技术与应用讲座于4月16日圆满落下帷幕,共有五百余名来自于高校科研院所、企事业单位、医院人员参加了此次盛会。时玉舫、肖磊、牛新乐、朱剑虹、刘伟、周琪、赖良学、邓宏魁、裴端卿、杨黄恬、高翔、张岩、金颖等国内干细胞领域顶级专家出席了此次会议并做精彩的演讲,众专家结合自己的研究领域,客观上多角度、全方位的展示国内干细胞研究的最新进展。生物谷旗

怎样在国际权威杂志上发表科学论文[鲁白的讲座]

这是著名科学家鲁白先生的讲座,专门针对如何发表国际一流SCI杂志。鲁白发表了大量Nature, Science, Cell等文章,在华人中有较高的影响力。他的讲座通俗易懂,对于发表和设计高级别SCI论文极有好处。 how to publish papers on international Journals.pdf

Baidu
map
Baidu
map
Baidu
map